Huntsman Cancer Institute Holmen Lab

Publications

View all Holmen SL publications in Google Scholar or PubMed

 

Selected Recent Publications:

Mutant IDH1 Promotes Glioma Formation In Vivo

Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen SL. Cell Rep (2018) 23:1553-1564.


Resistance mechanisms to genetic suppression of mutant NRAS in melanoma
Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW. Melanoma Res (2017) 27:545-557
Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, Holmen SL, Sharpless NE, Hugo W, Lo RS
Cancer Discovery (2017) doi:10.1158/2159-8290

HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss
Shin CH, Robinson JP, Sonnen JA, Welker AE, Yu DX, VanBrocklin MW, Holmen SL
Oncogene (2016) 2:311-329


AKT1 activation promotes development of melanoma metastases
Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL
Cell Reports (2015) 13:898-905

Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.
VanBrocklin MW, Robinson JP, Lastwika KJ, Khoury JD, Holmen SL
Pigment Cell Melanoma Res (2010) 23:531-41


Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.
Robinson JP, VanBrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL.
Oncogene (2010) 29:335-44